Monopar Therapeutics’ (MNPR) “Overweight” Rating Reaffirmed at Piper Sandler

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “overweight” rating reaffirmed by equities researchers at Piper Sandler in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $76.00 price objective on the stock. Piper Sandler’s target price suggests a potential upside of 121.12% from the stock’s current price.

Separately, HC Wainwright increased their price objective on shares of Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd.

Monopar Therapeutics Trading Up 0.4 %

Monopar Therapeutics stock opened at $34.37 on Wednesday. The firm has a 50-day moving average price of $36.16 and a 200-day moving average price of $21.99. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a market capitalization of $209.73 million, a PE ratio of -17.45 and a beta of 1.18.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MNPR. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Geode Capital Management LLC grew its position in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after buying an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth about $2,861,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the fourth quarter worth approximately $13,182,000. Finally, RA Capital Management L.P. acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.